Please login to the form below

tenofovir disoproxil

This page shows the latest tenofovir disoproxil news and features for those working in and with pharma, biotech and healthcare.

MSD claims EU approval for two HIV products

The pair – non-nucleoside reverse transcriptase inhibitor (NNRTI) Pifeltro (doravirine) and single-tablet combination Delstrigo (doravirine, lamivudine and tenofovir disoproxil fumarate) – are a much-needed bolster for Merck’s HIV portfolio,

Latest news

ViiV chalks up another win for two-drug HIV regimen

effects. Last month for example, ViiV showed that an oral formulation of Tivicay with nucleoside RTI Epivir (lamivudine) was as effective as a three-drug cocktail of dolutegravir plus tenofovir disoproxil ... Gilead’s new fixed-dose Biktarvy
GSK two-drug trial in untreated HIV raises Gilead rivalry

The combination of integrase inhibitor Tivicay (dolutegravir) with nucleoside reverse transcriptase inhibitor Epivir (lamivudine) had similar efficacy to treatment with dolutegravir plus tenofovir disoproxil fumarate and emtricitabine – two
ViiV starts trial of HIV-preventing injections for women

can defend against the spread of the virus as well as daily dosing with Gilead’s oral pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil).
People at-risk of HIV in England could get PrEP from September

The study of Gilead's pre-exposure prophylaxis (PrEP) therapy Truvada (emtricitabine and tenofovir disoproxil) - which was approved by the EMA last year - follows a pilot that saw the drug prevent
Gilead plans fightback against HIV arch-rival ViiV

The fixed dose combination of integrase strand inhibitor bictegravir with the two active ingredients in Descovy - emtricitabine and tenofovir alafenamide - met its main objective of non-inferiority to ViiV Healthcare's ... The drug is an upgrade to

More from news
Approximately 5 fully matching, plus 35 partially matching documents found.

Latest Intelligence

Choices, choices: the rapidly evolving HIV treatment landscape

With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

Account Director – UK Office: Excellent salary and benefits

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Account Director, Healthcare Communications: Salary TBC

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Subscribe to our email news alerts

PMHub

Add my company

Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...